ChromaDex Corporation (CDXC) financial statements (2022 and earlier)

Company profile

Business Address 10900 WILSHIRE BLVD
LOS ANGELES, CA 90024
State of Incorp. DE
Fiscal Year End December 31
SIC 2833 - Medicinal Chemicals and Botanical Products (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments28,21933,10238,77844,69116,69715,47818,890
Cash and cash equivalents28,21933,10238,77844,69116,69715,47818,890
Receivables5,2265,2955,999(1,500)(1,100)2,2142,854
Inventory, net of allowances, customer advances and progress billings13,60112,67612,18312,76211,68311,03112,338
Inventory13,60112,67612,18312,76211,68311,03112,338
Other undisclosed current assets1,8591,7629727,2664,9392,0051,684
Total current assets:48,90552,83557,93263,21932,21930,72835,766
Noncurrent Assets
Operating lease, right-of-use asset4,3523,0493,1821,1001,2261,323705
Property, plant and equipment 3,0843,1503,0583,2063,3073,487
Intangible assets, net (including goodwill)8579089611,0221,0821,1471,189
Intangible assets, net (excluding goodwill)8579089611,0221,0821,1471,189
Regulated entity, other noncurrent assets59      
Other noncurrent assets723576617594625910845
Other undisclosed noncurrent assets2,944      
Total noncurrent assets:8,9357,6177,9105,7746,1396,6876,226
TOTAL ASSETS:57,84060,45265,84268,99338,35837,41541,992
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities16,90417,13515,53919,02115,57812,05415,026
Accounts payable10,42310,8049,97011,6939,4456,8819,780
Accrued liabilities6,4816,3315,5697,3286,1335,1735,246
Deferred revenue161175210    
Debt201313504620733766
Other undisclosed current liabilities528447467231278228250
Total current liabilities:17,61317,77016,22919,75616,47613,01516,042
Noncurrent Liabilities
Long-term debt and lease obligation4,1542,8873,0309641,0171,093549
Finance lease, liability 111317202327
Operating lease, liability4,1542,8763,0179479971,070522
Liabilities, other than long-term debt4,3464,3464,4414,4414,4413,8203,820
Deferred revenue4,3464,3464,4414,4414,4413,8203,820
Total noncurrent liabilities:8,5007,2337,4715,4055,4584,9134,369
Total liabilities:26,11325,00323,70025,16121,93417,92820,411
Stockholders' equity
Stockholders' equity attributable to parent, including:31,72735,44942,14243,83216,42419,48721,581
Common stock68686868626261
Additional paid in capital200,614199,011196,848192,972158,190155,156153,036
Accumulated deficit(168,953)(163,628)(154,772)(149,206)(141,825)(135,728)(131,513)
Other undisclosed stockholders' equity attributable to parent(2)(2)(2)(2)(3)(3)(3)
Total stockholders' equity:31,72735,44942,14243,83216,42419,48721,581
TOTAL LIABILITIES AND EQUITY:57,84060,45265,84268,99338,35837,41541,992

Income statement (P&L) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Revenues17,75917,30817,69914,68315,44514,18015,287
Revenue from related parties2,2002,6002,900 2,1002,5002,900
Cost of revenue(6,891)(6,730)(6,889)(5,449)(6,024)(5,726)(6,199)
Gross profit:10,86810,57810,8109,2349,4218,4549,088
Operating expenses(16,184)(19,419)(16,364)(16,596)(15,502)(12,650)(12,775)
Operating loss:(5,316)(8,841)(5,554)(7,362)(6,081)(4,196)(3,687)
Nonoperating expense   (19)(16)(19)(24)
Interest and debt expense(9)(15)(12)(19)(16)(19)(24)
Loss before gain (loss) on sale of properties:(5,325)(8,856)(5,566)(7,400)(6,113)(4,234)(3,735)
Other undisclosed net income   20   
Net loss:(5,325)(8,856)(5,566)(7,380)(6,113)(4,234)(3,735)
Other undisclosed net income (loss) attributable to parent   (1)161924
Net loss available to common stockholders, basic:(5,325)(8,856)(5,566)(7,381)(6,097)(4,215)(3,711)
Other undisclosed net income available to common stockholders, diluted    11,914  
Net income (loss) available to common stockholders, diluted:(5,325)(8,856)(5,566)(7,381)5,817(4,215)(3,711)

Comprehensive Income ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Net loss:(5,325)(8,856)(5,566)(7,380)(6,113)(4,234)(3,735)
Comprehensive loss, net of tax, attributable to parent:(5,325)(8,856)(5,566)(7,380)(6,113)(4,234)(3,735)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: